Dr. Kenneth Edelson

GLG News by Dr. Kenneth Edelson, Associate Clinical Professor of Dermatology

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Cost is key, but not enough!

December 17, 2007

Analysis of:Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com

Lowering cost of Botox is key, but not enough to induce patients to undergo Botox treatments.

Reloxin Gives Allergan's Botox A Run for the Money!

December 13, 2007

Analysis of:Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com

For too long Allergan has monopolized the therapeutic and cosmetic market of botulinum toxin type A, and has taken full advantage of that monopoly by raising the price of Botox almost biannually. Reloxin studies are very favorable when compared to Botox, and may even surpass it in one or two aspects. There is a lesser protein load and therefore less antigenic than Botox and this may lead to a longer lasting effect. Studies already show and support this. In addition, there is a greater diffusion of the toxin from pontiff injection, and this is desirable in certain areas as the large frontalis areas of the face, and certainly in the large areas we tret for hyperhidrosis of the palms, soles and axillae, The conversion rate of units is not to be looked at as a chore of conversion, but as learning a new language. Don't look to convert units to units...just learn the required units of the new toxin. The shelf life appears to be slily longer as well. Cudos to Reloxin-watch out Botox!

New Organiceuticals May Help Bring Back Beauty!

May 29, 2007

Analysis of:http://www.nytimes.com/2007/04/26/fashion/26skin.html?_r=1&ref=health&oref=slogin | www.nytimes.com

All that glitters is not gold...but some might be! Anti-oxidants are the promise of saving our "hides"!

Couldn't agree more

May 28, 2007

Analysis of:FDA May Place Ban on OTC Bleaching Creams | www.carefair.com

Keep Hydroquinones Around!

Non-Invasive Screening of the Skin

May 17, 2007

Analysis of:New tool allows noninvasive screening of skin lesions | www.modernmedicine.com

The company hopes to apply for European regulatory approval next year, with U.S. market approval and launch to follow. The current price of the device is 15,000 EUR. This device promises to be a remarkable time and money saver for medicine. Approximately 80-95% of lesions excised by dermatologists prove non-cancerous when examined histologically. This is wasted time, money and unnecessary anxiety for patients.

Pulsed Dye Vs Excimer Laser for Psoriasis

May 17, 2007

Analysis of:Psoriasis Challenge: pulsed dye vs. excimer lasers | www.modernmedicine.com

Patient satisfaction is high, but long term effects including possible carcinogenesis remain uncertain. Side effects included blistering, and hyperpigmentation in both groups, but no scarring.

Non-Invasive Screening of the Skin

April 3, 2006

Analysis of:New tool allows noninvasive screening of skin lesions | www.dermatologytimes.com

The company hopes to apply for European regulatory approval next year, with U.S. market approval and launch to follow. The current price of the device is 15,000 EUR. This device promises to be a remarkable time and money saver for medicine. Approximately 80-95% of lesions excised by dermatologists prove non-cancerous when examined histologically. This is wasted time, money and unnecessary anxiety for patients.

Silicone Breast Implant Approval Closer

April 3, 2006

Analysis of:FDA Statement on Approvable Letter to Mentor Corporation. Mentor Receives Approva | www.fda.gov

I think women have been well informed for a while about the nature of silicone implants, and they should be allowed to make a personal decison for themselves. The commercial implications are very obvious. There will now be a resurgence of silicone implant popularity and new competition for that market.

Immunization Appears to Offer Protection Against Atopic Disease

April 3, 2006

Analysis of:Does childhood immunization against infectious diseases protect from the development of atopic disea | www.blackwell-synergy.com

The results imply that children not exposed to allergens in the environment are more likely to develop asthma, atopic dermatitis, and other allergic responses.

General Anesthesia Risk is Low for Pediatric Procedures

April 3, 2006

Analysis of:General anesthesia for pediatric dermatologic procedures: risks and complications | www.ncbi.nlm.nih.gov

The authors concluded that this, the largest study of its kind to date, the use of general anesthesia during pediatric dermatology procedures appears safe, with a risk of 1:20,000 to 1:80,000 or less.

Tacrolimus-Safe Treatment for Atopic Dermatitis

April 3, 2006

Analysis of:SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis | www.blackwell-synergy.com

The ideal treatment is to use a dilute steroid along with the tacrolimus for best results.

Pulsed Dye Vs Excimer Laser for Psoriasis

April 3, 2006

Analysis of:Psoriasis Challenge: pulsed dye vs. excimer lasers | www.dermatologytimes.com

Patient satisfaction is high, but long term effects including possible carcinogenesis remain uncertain. Side effects included blistering, and hyperpigmentation in both groups, but no scarring.

Artefill Nears Final FDA Approval

April 3, 2006

Analysis of:Artefill Nears Final Approval Despite Critics' Cautions: Granuloma formation is biggest concern | www.eskinandallergynews.com

The granulomas can be a nightmare for the patient. It will not be approved for lip augmentation, and there are other requiremnets that the FDA has imposed on Artes Medical, Inc., prior to its approval.

Topical Sirolimus for Psoriasis

April 3, 2006

Analysis of:Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blin | www.blackwell-synergy.com

Topical therapy in dermatology is fascinating. The drug must not only be efficacious molecules, but be able to penetrate the strateum corneum to reach the level of pathology. The topical results shown in this study were statistically significant, but the clinical benefit seemed modest.

Page : 11 to 14 of 14